ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2028

Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort

Thomas Krams1, Adeline Ruyssen-Witrand2, Delphine Nigon1, Bruno Fautrel3,4,5, Francis Berenbaum6,7, Alain G. Cantagrel8 and Arnaud Constantin9, 1Rhumatologie, Purpan University Hospital, Toulouse, France, 2Rheumatology, Purpan University Hospital, Toulouse, France, 3Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 4Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, 5Rheumatology, Pitie Salpetriere Hospital, Paris, France, 6Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, 7INSERM - UMR S 938, Paris, France, 8Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 9Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Health Assessment Questionnaire, radiography, remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Rheumatoid arthritis (RA) is a chronic disease with peak incidence in the fourth and fifth decades of age. To investigate whether age at disease onset determines clinical, radiographic or functional outcomes in a cohort of early RA, taking into consideration possible age-related differences in treatment modalities. 

Methods:

The ESPOIR cohort is a longitudinal, prospective, multicenter, observational study of adult patients with early arthritis. For this study, we selected data for patients fulfilling the 2010 American College of Rheumatology/European League Against Rheumatism criteria for RA during the first 3 years of follow-up. Patients were pooled into 3 groups by age at RA onset: <45 years (young-onset RA [YORA]), 45 to 60 years (intermediate-onset RA [IORA]) and >60 years (late-onset RA [LORA]). The following outcomes were compared at baseline and during the first 3 years of follow-up by age at disease onset: Simple Disease Activity Index (SDAI) remission rate, one additional erosion, and Health Assessment Questionnaire Disability Index (HAQ-DI) score < 0.5. We also assessed first disease-modifying anti-rheumatic drug (DMARD) survival rate. A multivariate model (logistic regression) was built.

Results:

We included 698 RA patients (median [interquartile range] age 50.3 [39.8-57.2] years; female 78.2%), 266 YORA, 314 IORA, and 118 LORA. The median SDAI was 28.5 (20.6-38.6) and median HAQ-DI score 1 (0.5-1.5). At 1 year, SDAI remission was greater for patients with YORA than IORA and LORA (<0.0001). Having at least one additional erosion was greater for LORA and IORA than YORA patients after 1 year (41.1% [39/95] and 29.7% [81/272] vs 23.8% [51/214], p=0.009) and 3 years (48.2% [41/85] and 44.3% [105/237] vs 32.81% [63/192], p=0.017). The proportion of patients with HAQ score < 0.5 was greater for YORA than IORA and LORA at 1 year (p=0.007) and remained significant at 2 and 3 years. The first DMARD survival rate was lower for YORA than IORA and LORA patients during the 3 years (p=0.005). On multivariate analysis, young age at RA onset was independently associated with SDAI remission at 1 year, no additional erosion at 3 years and HAQ score < 0.5 at 1, 2 and 3 years.

Conclusion:

In a cohort of early RA, young age at disease onset is associated with high rate of remission at 1 year, low radiographic progression at 3 years and low functional score during 3-year follow-up. Young age at disease onset is associated with low first DMARD survival rate over 3 years, which suggests that late-onset RA patients may receive less aggressive treatment strategies than younger patients.


Disclosure:

T. Krams,
None;

A. Ruyssen-Witrand,
None;

D. Nigon,
None;

B. Fautrel,
None;

F. Berenbaum,

Merck, Pfizer Inc, Roche, Bristol-Myers Squibb, and UCB ,

2,

AbbVie, Roche, and UCB,

5;

A. G. Cantagrel,
None;

A. Constantin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-age-at-rheumatoid-arthritis-onset-on-clinical-radiographic-and-functional-outcomes-the-espoir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology